Portal Hypertension: Causes, Diagnosis, Varices, and Treatment in India

What Is Portal Hypertension?

The portal vein carries blood from the intestines and spleen to the liver. Portal hypertension is a rise in pressure within this system — defined as a hepatic venous pressure gradient (HVPG) above 5 mmHg. When HVPG reaches 10 mmHg or more, it becomes clinically significant: the point at which varices begin to form and ascites can develop. At 12 mmHg or above, the risk of variceal bleeding rises sharply.

Portal hypertension is not a disease in itself but a consequence — most often of cirrhosis, but sometimes of vascular or inflammatory conditions that obstruct blood flow before it enters the liver. Understanding what has blocked the portal circulation determines both the prognosis and the treatment.

Causes and Who Is at Risk

In India, cirrhosis is responsible for the majority of portal hypertension cases. Alcohol-related liver disease, hepatitis B, hepatitis C, and metabolic-associated steatotic liver disease (MASLD) are the leading drivers. As the liver scars over years, its architecture distorts, vascular resistance rises, and the portal system bears the brunt.

India has a higher burden of non-cirrhotic portal hypertension (NCPH) than most Western countries. Two forms are especially relevant here:

• Extrahepatic portal vein obstruction (EHPVO): A clot in the portal vein, often from a neonatal infection or a prothrombotic disorder, that obstructs flow before it enters the liver. Common in children and young adults. The liver itself may be entirely normal.
• Non-cirrhotic intrahepatic portal hypertension (NCIPH): A heterogeneous group of conditions — including nodular regenerative hyperplasia and porto-sinusoidal vascular disorder — where resistance is raised within the liver without classical cirrhosis.

Less common causes include Budd-Chiari syndrome (hepatic vein thrombosis), right heart failure causing back-pressure, and schistosomiasis (relevant in parts of eastern India). Risk factors across all causes: prothrombotic states, long-term exposure to certain medications or toxins, and chronic viral hepatitis without adequate treatment.

Symptoms and Complications

Portal hypertension is often silent for years. When it declares itself, it does so through its complications:

• Gastroesophageal varices: Dilated veins in the oesophagus and stomach that form as the portal system seeks alternative drainage routes. They bleed without warning — and when they do, it is a medical emergency.
• Ascites: Fluid accumulating in the abdomen. Patients notice abdominal swelling, weight gain, and breathlessness as the diaphragm is pushed upward.
• Hepatic encephalopathy: Confusion, altered sleep, flapping tremor (asterixis), and — in severe cases — coma, driven by ammonia and other toxins bypassing the liver.
• Splenomegaly and hypersplenism: An enlarged spleen sequesters platelets and white cells, causing thrombocytopenia and increased infection risk.
• Hepatorenal syndrome: Kidney failure secondary to circulatory dysfunction, one of the gravest complications of decompensated disease.

Diagnosis

Diagnosis begins with clinical suspicion — a patient with known liver disease, an unexpectedly low platelet count, or a spleen that has grown too large. From there, the workup is layered:

Doppler ultrasound is the first investigation. It can visualise the portal vein, estimate flow velocity, detect splenomegaly, and identify ascites. It is non-invasive, widely available, and the standard initial step.

Liver stiffness measurement (FibroScan/transient elastography) is increasingly used to predict clinically significant portal hypertension non-invasively. A liver stiffness above 25 kPa in a patient with known liver disease has a high specificity for HVPG ≥ 10 mmHg, per EASL guidance. When combined with platelet count — the Baveno VII criteria — it can safely avoid endoscopy in a substantial proportion of compensated patients.

Upper GI endoscopy remains essential for directly visualising varices, grading their size, and identifying high-risk stigmata (red wale marks, cherry red spots) that predict imminent bleeding.

HVPG measurement — via transjugular hepatic venography — is the gold standard. It guides treatment decisions, particularly in clinical trials and refractory cases, but is performed selectively in India given its invasive nature.

CT or MRI of the abdomen is used when vascular anatomy needs clarification — especially for portal vein thrombosis, Budd-Chiari syndrome, or pre-transplant assessment.

Treatment

Management is stratified by the clinical stage — compensated, decompensated, or acutely bleeding — and by the underlying cause.

Primary prophylaxis (preventing the first bleed): For patients with medium or large oesophageal varices, or small varices with high-risk features, the APASL consensus on portal hypertension and EASL clinical practice guidelines recommend non-selective beta-blockers (NSBBs) as first-line pharmacological therapy. Carvedilol (12.5 mg daily) is preferred over propranolol in many centres because of its dual action — blocking both portal blood flow and intrahepatic resistance. Endoscopic variceal ligation (EVL) is an effective alternative when beta-blockers are not tolerated.

Acute variceal haemorrhage: This is a life-threatening emergency. The priority is resuscitation, restrictive blood transfusion (targeting haemoglobin of 7–8 g/dL), and immediate vasoactive therapy — terlipressin is the vasoactive drug of choice in India and is supported by AASLD and APASL guidelines. Emergency endoscopy within 12 hours, with EVL as the preferred technique, is standard. Prophylactic antibiotics — ceftriaxone 1g intravenously daily for up to seven days — reduce the risk of infection and rebleeding and are recommended by all major societies. In high-risk patients (Child-Pugh C or HVPG ≥ 20 mmHg), early TIPS within 72 hours of the index bleed has been shown to substantially improve survival.

Secondary prophylaxis (preventing rebleeding): The combination of NSBBs plus EVL is the standard of care. Neither alone is as effective as the two together.

Ascites: Salt restriction (less than 2g sodium daily), spironolactone (starting at 50–100 mg daily, titrated up), and furosemide as needed. Large-volume paracentesis with intravenous albumin infusion (8g per litre of ascites removed) for refractory cases.

TIPS (Transjugular Intrahepatic Portosystemic Shunt): A stent placed between the hepatic and portal veins that decompresses the portal system. Used for refractory variceal bleeding, refractory ascites, and certain cases of hepatic hydrothorax. PTFE-covered stents have significantly improved patency rates. TIPS is not appropriate in all patients — hepatic encephalopathy, advanced heart failure, and polycystic liver disease are relative contraindications.

Liver transplantation is the definitive treatment for portal hypertension secondary to end-stage liver disease. At Gleneagles Hospital Mumbai, Dr. Chetan Kalal’s programme offers transplant evaluation and listing for patients with decompensated cirrhosis, including those with refractory complications of portal hypertension. For NRI patients from the UK, USA, UAE, Canada, and Australia, teleconsultation appointments are available to plan the diagnostic workup and coordinate treatment.

Frequently Asked Questions

Q: Can portal hypertension be reversed?
In cirrhosis, the structural damage is largely irreversible, but the functional component of elevated resistance can improve with treatment of the underlying cause — antiviral therapy for hepatitis B and C, alcohol abstinence in alcoholic liver disease, or weight loss in MASLD. In early-stage or compensated patients, treating the underlying liver disease can reduce HVPG to below the clinical threshold. In non-cirrhotic causes such as EHPVO, the liver itself is unaffected, and anticoagulation can restore portal patency in selected cases.

Q: Are beta-blockers safe to take long-term for portal hypertension?
Yes, in appropriately selected patients. Carvedilol and propranolol are well-tolerated when introduced at low doses and titrated gradually. They are not recommended in patients with refractory ascites (where they may compromise circulatory reserve), significant hypotension (systolic BP below 90 mmHg), or severe bronchospasm. Regular follow-up allows dose adjustment if side effects develop.

Q: When does a patient with portal hypertension need liver transplantation?
Transplantation is considered when portal hypertension has caused irreversible decompensation — recurrent variceal bleeding despite optimal endoscopic and pharmacological therapy, refractory ascites, recurrent spontaneous bacterial peritonitis, or hepatic encephalopathy that impairs daily life. The MELD score is used to prioritise transplant listing. Patients with cirrhosis should ideally be referred to a transplant hepatologist before they reach a critical threshold.

Q: Can portal hypertension develop in someone without liver disease?
Yes — and this is more common in India than in Western populations. Extrahepatic portal vein obstruction (EHPVO) causes significant portal hypertension with a completely normal liver. These patients, often young adults or even children, present with massive splenomegaly and variceal bleeding but have preserved hepatic function. The prognosis is generally better than cirrhosis-related portal hypertension, though long-term anticoagulation, endoscopic surveillance, and surgical shunting are sometimes required.

---

Author: Dr. Chetan Kalal — Consultant Hepatologist and Liver Transplant Physician, Gleneagles Hospital Mumbai. First DM Hepatologist of Maharashtra. AASLD Foundation Award 2016 and 2017. FNAMS 2022–23. ORCID: 0000-0002-5284-7890 | PubMed publications.